discoveri
tlr
famili
precis
function
open
varieti
gate
modul
immunolog
host
respons
tlr
locat
endosom
compart
activ
specif
signal
pathway
manner
accord
involv
variou
autoimmun
inflammatori
malign
diseas
research
design
divers
tlr
ligand
abl
boost
block
inher
signal
transduct
modul
often
small
synthet
compound
act
agonist
much
lesser
extent
antagonist
reach
preclin
clinic
trial
one
approv
fda
ema
imiquimod
key
success
modul
probabl
lie
combin
therapi
recent
demonstr
gather
review
scientif
public
review
patent
relat
extens
work
carri
research
design
tlr
modul
classifi
firstli
biolog
activ
agonist
antagonist
chemic
structur
total
synthes
discuss
review
also
report
clinic
case
therebi
show
biolog
interest
modul
multipl
patholog
innat
immun
compos
sever
famili
pattern
recognit
receptor
ppr
latter
receptor
serv
identifi
pathogenassoci
molecular
pattern
pamp
dangerassoci
molecular
pattern
damp
ppr
act
primari
defens
pathogen
entiti
control
activ
progress
adapt
immun
activ
product
proinflammatori
cytokin
chemokin
interferon
also
b
cell
among
ppr
tolllik
receptor
tlr
special
interest
discoveri
year
ago
improv
knowledg
regul
innat
immun
inflamm
cytokin
induct
tlr
divid
two
group
depend
subcellular
local
larg
correl
type
molecular
pattern
abl
recogn
among
endosom
tlr
tlr
agonist
fig
mani
novel
tlr
agonist
differ
chemic
seri
develop
last
year
immunostimul
activ
agonist
allow
interven
therapi
sever
diseas
valuabl
vaccin
adjuv
candid
contrast
chronic
immun
activ
sustain
tlr
activ
hallmark
sever
infecti
autoimmun
malign
diseas
therefor
develop
tlr
antagonist
may
also
play
import
role
therapi
diseas
evid
therapeut
potenti
tlr
ligand
prompt
mani
pharmaceut
compani
research
institut
design
synthet
optim
tlr
modul
research
team
attach
great
import
immunomodulatori
potenti
heterocycl
known
antitumor
antiparasit
activ
structur
analog
synthet
imidazo
quinoxalin
pyrazolo
quinoxalin
imidazo
pyrazin
imiquimod
set
futur
line
research
chemistri
biolog
allow
us
focu
tlr
immunomodulatori
effect
biand
tricycl
deriv
review
gather
public
januari
relat
modul
extent
data
show
review
modul
tlr
activ
easi
despit
mani
sar
studi
around
variou
recogn
chemic
core
minim
structur
also
macromolecul
consid
prepar
research
first
chapter
briefli
present
data
concern
express
structur
signal
pathway
inform
help
better
understand
import
target
receptor
interest
prepar
compound
abl
modul
inher
biolog
respons
focu
second
third
chapter
implic
agonist
antagonist
respect
therapeut
treatment
describ
natur
synthet
ligand
focus
mainli
small
organ
compound
final
chapter
expos
clinic
case
use
agonist
antagonist
ligand
clearli
refer
receptor
tlr
express
immun
cell
macrophag
dendrit
cell
b
cell
neutrophil
natur
killer
cell
nk
monocyt
eosinophil
nonimmun
cell
fibroblast
keratinocyt
epitheli
cell
intestin
respiratori
urogenit
tract
identifi
mice
human
express
cellular
plasma
membran
express
endosom
membran
mice
human
endosom
receptor
specif
mice
predominantli
express
plasmacytoid
dendrit
cell
pdc
b
cell
low
level
also
observ
nonimmun
cell
hepatocyt
epitheli
cell
keratinocyt
contrari
strongli
express
myeloid
dendrit
cell
monocyt
lesser
extent
pdc
certain
circumst
express
induc
cell
express
basal
undetect
level
includ
immun
cell
macrophag
myeloid
dendrit
cell
nonimmun
cell
hepatocyt
keratinocyt
exampl
mrna
express
induc
stimul
ifng
macrophag
level
similarli
viral
infect
hepat
c
human
immunodefici
viru
hiv
influenza
viru
lead
upregul
express
hepatocyt
circul
immun
cell
primari
macrophag
respect
circumst
seem
cytokin
induc
viral
infect
respons
trigger
induct
express
fact
infect
primari
macrophag
influenza
viru
lead
upregul
mrna
type
ifn
depend
manner
addit
increas
express
tlr
observ
cancer
autoimmun
diseas
rheumatoid
arthriti
system
lupu
erythematosu
sle
tlr
compos
extracellular
domain
leucinerich
repeat
motif
lrr
respons
recognit
pathogen
element
pamp
andor
damp
transmembran
domain
cytoplasm
domain
compris
receptor
tir
homolog
receptor
consequ
respons
signal
transduct
tlr
interact
pamp
damp
homo
heterodim
along
coreceptor
accessori
molecul
tlr
receptor
type
high
degre
sequenc
homolog
function
similar
basic
tlr
signal
divid
two
pathway
pathway
trifdepend
pathway
activ
pathway
lead
recruit
phosphoryl
express
ifnb
way
involv
signal
pathway
give
detail
fact
signal
pathway
depend
protein
fig
compos
tir
domain
death
domain
follow
activ
tlr
interact
death
domain
death
domain
member
irak
receptorassoci
kinas
protein
kinas
famili
includ
irakm
phosphoryl
activ
phosphoryl
two
kinas
dissoci
interact
ubiquitin
ligas
activ
togeth
ubiquitin
conjug
enzym
favor
lysinerel
polyubiquitin
protein
kinas
complex
latter
member
mapkkk
famili
form
complex
regulatori
subunit
interact
polyubiquitin
chain
allow
activ
activ
two
signal
pathway
nfkb
mapk
pathway
ikk
complex
compos
two
catalyt
subunit
ikka
ikkb
regulatori
subunit
nemo
ikkg
bind
ikk
complex
via
ubiquitin
chain
allow
phosphoryl
activ
ikkb
ikk
complex
phosphoryl
inhibitori
protein
nfkb
ikba
undergo
degrad
cytoplasm
thu
allow
nfkb
transloc
nucleu
induc
express
proinflammatori
gene
addit
also
activ
member
mapk
famili
jnk
mediat
activ
transcript
factor
respons
express
proinflammatori
cytokin
ifnb
fig
moreov
ito
et
al
show
express
myeloid
plasmacytoid
dendrit
cell
studi
product
ifna
dendrit
cell
agonist
stimul
found
cytokin
induct
pattern
differ
myeloid
dendrit
cell
mdc
pdc
pdc
produc
ifna
mdc
produc
given
larg
amount
ifna
produc
pdc
express
tlr
much
work
publish
literatur
elucid
signal
pathway
lead
activ
secret
ifna
especi
dendrit
cell
induc
antivir
respons
product
ifna
well
proinflammatori
cytokin
three
receptor
use
adapt
protein
initi
signal
pathway
transcript
factor
interferon
regulatori
factor
respons
express
product
ifna
interact
directli
endosom
also
interact
anoth
adapt
molecul
oper
downstream
receptor
activ
tlr
activ
depend
manner
splenic
pdc
mice
show
signific
decreas
ifna
induct
follow
viral
infect
exposur
synthet
ligand
hand
induct
normal
pdc
show
induct
ifna
pdc
requir
addit
mutat
studi
shown
protein
interact
via
death
domain
death
domain
also
interact
serin
threonin
kinas
famili
irak
transduc
signal
indic
irak
involv
signal
pdc
mice
unabl
produc
ifna
upon
activ
tlr
addit
one
studi
shown
ikka
also
essenti
activ
indic
activ
requir
cascad
protein
kinas
studi
also
shown
play
import
role
signal
addit
also
interact
unlik
bind
death
domain
interact
middl
region
known
intermedi
domain
part
tir
domain
activ
signal
pathway
ligand
lead
transloc
nucleu
activ
express
proinflammatori
cytokin
schoenemey
et
al
shown
stimul
resiquimod
induc
activ
well
also
found
central
mediat
tlr
signal
pathway
contribut
induct
ifn
type
human
cell
addit
import
ifna
induct
also
ifnb
induct
studi
show
mdc
pdc
macrophag
capabl
induc
larg
amount
ifnb
bacteri
degrad
phagolysosom
respons
requir
intervent
consequ
signal
pathway
lead
activ
transcript
factor
nfkb
regul
express
inflammatori
cytokin
ifn
induc
gene
briefli
despit
phylogenet
structur
similar
tlr
differ
function
cytokin
profil
induc
human
pbmc
well
pbmcisol
cell
popul
function
associ
product
ifna
involv
product
proinflammatori
cytokin
tnfa
tlr
signal
pathway
activ
innat
immun
help
modul
adapt
immun
henc
essenti
use
develop
immunotherapi
clinic
trial
two
third
tlr
agonist
ligand
first
exploit
adjuv
versu
one
third
potent
drug
variou
therapi
herein
therapeut
purpos
agonist
ligand
tlr
discuss
natur
synthet
ligand
present
respons
viral
infect
host
activ
innat
immun
system
whose
respons
character
ifn
inflammatori
cytokin
chemokin
product
respons
viral
infect
mediat
sever
tlr
signal
pathway
includ
tlr
contribut
tlr
differ
depend
viru
cell
type
infect
model
examin
abl
detect
gurich
aurich
ssrna
sequenc
rna
virus
known
serv
endosom
prr
number
ssrna
virus
influenza
vesicular
stomat
viru
sendai
viru
flavivirus
coronavirus
moreov
signal
well
describ
human
mice
type
ifn
product
pdc
respons
ssrna
viral
stimuli
signal
mainli
result
nfkb
activ
subsequ
inflammatori
cytokin
express
shortli
descript
shown
receptor
respond
potent
antivir
imidazoquinolin
compound
low
molecular
weight
synthet
compound
shown
mediat
inflammatori
respons
tlr
play
key
role
antivir
antibacteri
respons
vaccin
imprint
immun
system
experi
pathogen
exposur
result
product
humor
immun
respons
agspecif
memori
b
cell
efficaci
result
immun
strongli
vari
ingredi
vaccin
vaccin
employ
earli
stage
vaccinolog
live
attenu
kill
organ
adjuv
systemat
requir
current
employ
adjuv
human
vaccin
aluminum
salt
oil
water
emuls
eg
adjuv
limit
requir
multipl
administr
induc
protect
drive
immun
moreov
vaccinolog
move
toward
use
inactiv
antigen
lack
immunolog
inform
need
enhanc
adapt
immun
respons
henc
develop
novel
adjuv
deliveri
system
replac
one
actual
use
becom
crucial
improv
vaccineinduc
protect
immun
togeth
mediat
recognit
purinerich
ssrna
elicit
immun
respons
pathogen
recogn
endosom
tlr
implic
recognit
natur
deriv
uridineerich
ssrna
influenza
hiv
addit
recogn
bacteri
rna
furthermor
express
human
plasmacytoid
dc
pdc
b
cell
monocyt
macrophag
naiv
human
b
cell
express
low
level
wherea
activ
memori
human
b
cell
also
express
broader
rang
tlr
includ
b
cell
intrins
signal
may
play
role
b
cell
respons
chronic
infect
could
use
activ
memori
b
cell
boost
humor
immun
respons
immun
synthet
small
molecul
agonist
activ
tlr
could
use
adjuv
identifi
present
herein
howev
challeng
develop
molecul
remain
formul
specif
potent
immunostimulatori
molecul
target
tlr
lead
stimul
innat
adapt
immun
product
cytokin
activ
cytotox
cell
tlr
agonist
could
promis
element
novel
therapi
wherea
mani
studi
suggest
activ
tlr
may
potenti
applic
oncotherapi
other
prove
tlr
signal
also
implic
tumorigenesi
even
fight
cancer
tlr
target
alway
investig
human
clinic
trial
often
fail
mani
patient
immunosuppress
due
tradit
anticanc
therapi
way
difficult
induc
posit
immun
respons
abl
help
organ
combat
tumor
understand
role
tlr
cancer
cell
type
remain
main
obstacl
clinic
therapeut
applic
combin
modul
tradit
approach
chemotherapi
radiotherapi
could
key
success
anticanc
therapi
primari
step
type
allerg
diseas
allerg
rhiniti
asthma
druginduc
anaphylaxi
usual
strong
proinflammatori
igemedi
respons
antigen
counterbalanc
induct
tlr
signal
induc
cytokin
respons
activ
antigen
present
cell
lead
respons
agonist
activ
tlr
particularli
would
expect
induc
strong
respons
focu
novel
therapeut
treat
asthma
allergi
among
allerg
diseas
asthma
complex
chronic
inflammatori
diseas
airway
character
airway
hyperrespons
eosinophil
infiltr
revers
airflow
obstruct
airway
remodel
mucu
hypersecret
goblet
cell
hyperplasia
asthma
affect
million
peopl
worldwid
allergi
atopi
main
caus
asthma
genet
environment
trigger
modul
activ
regul
immun
system
also
implic
pathophysiolog
asthma
bronchial
inflamm
smooth
muscl
spasm
mucu
product
allerg
asthma
trigger
releas
cell
ligand
play
import
role
reduct
airway
inflamm
promot
respons
immun
cell
revers
airway
hyperrespons
prevent
airway
remodel
includ
smooth
muscl
prolifer
goblet
cell
hyperplasia
acut
chronic
asthma
attack
manag
precis
identifi
regul
pathogen
pathway
target
molecular
mediat
given
structur
similar
firstli
describ
agonist
tlr
nucleic
acid
heil
et
al
studi
effect
singlestrand
ribonucl
acid
ssrna
activ
antigenpres
cell
via
show
guanosin
g
uridin
u
rich
oligonucleotid
induc
product
tnfa
human
pbmc
ssrna
natur
ligand
fig
year
diebold
et
al
shown
ssrna
influenza
viru
agonist
prefer
particular
rna
motif
uridin
addit
studi
shown
adenosineand
uridinerich
oligoribonucleotid
orn
capabl
activ
without
effect
guanosinerich
orn
activ
signal
quest
agonist
rang
chemic
modif
done
natur
orn
ligand
order
increas
select
andor
stabil
nucleas
tanji
et
al
show
first
time
recogn
ssrna
degrad
product
two
differ
site
first
site
recogn
uridin
second
recogn
short
orn
ug
uug
uridin
alon
abl
activ
absenc
orn
second
site
orn
bind
second
site
increas
affin
uridin
first
site
therefor
lead
activ
base
result
shibata
et
al
show
respond
guanosin
analogu
guanosin
deoxyguanosin
dg
presenc
oligoribonucleotid
fig
guanosin
alon
ssrna
alon
polyu
capabl
activ
howev
combin
lead
receptor
activ
similarli
ssrna
enhanc
affin
guanosin
dg
consid
nucleotid
metabolit
present
physiolog
patholog
state
consid
endogen
ligand
result
confirm
zhang
et
al
show
also
recogn
degrad
form
ssrna
guanosin
bind
first
site
oligonucleotid
polyu
bind
second
site
combin
two
product
activ
dimer
synergist
way
furthermor
mani
articl
publish
show
role
smallinterf
rna
sirna
stimul
immun
system
sirna
recognit
cytokin
releas
fabbri
et
al
show
tumorsecret
function
ligand
bind
murin
human
receptor
immun
cell
trigger
tlrmediat
prometastat
inflammatori
respons
ultim
may
lead
tumor
growth
metastasi
mani
synthet
ligand
potent
agonist
tlr
design
worldwid
classifi
review
increas
number
hetero
cycl
pyrimidin
purin
base
deriv
pyrimidin
deriv
smaller
fragment
first
describ
skulnick
et
al
bropirimin
also
known
abpp
fig
oral
activ
immunostimul
act
ifn
induc
sever
speci
immunomodul
macrophag
natur
killer
cell
cytokin
bropirimin
describ
antivir
antineoplast
agent
test
agent
melanoma
bladder
tumor
prostat
cancer
renal
cell
carcinoma
beesu
et
al
undergon
sar
studi
pyrimidin
seri
focus
substitu
modul
attempt
design
agonist
contain
benzimidazol
core
vaccin
adjuv
beesu
et
al
found
smallest
possibl
fragment
benzimidazol
core
allow
retent
activ
correspond
fig
crystal
structur
compound
bound
ectodomain
display
bind
interact
common
agonist
compound
show
mark
attenu
proinflammatori
properti
ex
vivo
human
blood
model
fig
test
potenti
secret
ifna
treatment
hcv
sar
studi
show
presenc
benzyl
group
posit
well
hydroxyl
group
compound
essenti
ifn
induct
introduct
r
substitu
alkyl
alkylthio
alkylamino
alkoxi
group
moieti
result
remark
increas
activ
analogu
show
import
activ
oral
administr
mice
ifninduc
activ
compound
time
higher
imiquimod
oral
administr
mice
furthermor
compound
better
oral
toler
compar
imiquimod
fig
mice
result
indic
compound
better
efficaci
safeti
profil
compar
imiquimod
base
data
kurimoto
et
al
synthes
seri
variou
alkoxi
alkylthio
group
evalu
abil
induc
ifn
vitro
vivo
found
also
known
fig
potent
induc
ifn
good
oral
bioavail
agonist
abl
activ
immun
respons
hcv
shown
lee
et
al
induc
ifna
human
peripher
blood
mononuclear
cell
ec
valu
mm
mm
shown
reduc
hcv
level
h
human
hepatocyt
cell
line
carri
hcv
replicon
induc
ifn
mice
minim
effect
dose
approxim
mgkg
make
approxim
potent
imiquimod
mechan
action
still
studi
notabl
russo
et
al
show
higher
concentr
agonist
miic
pdc
acid
compart
proton
charg
posit
compound
potenti
treatment
hepat
c
also
colon
cancer
select
potent
agonist
fig
display
minimum
effect
concentr
mec
nm
compar
resiquimod
fig
demonstr
potent
dose
mgkg
oral
administr
mice
dose
depend
manner
ifninduc
activ
monkey
caus
emesi
ferret
even
dose
mgkg
isob
et
al
also
show
maximum
plasma
concentr
ngml
ca
mm
approxim
higher
mec
valu
oral
administr
lead
induct
ifna
tnfa
activ
b
lymphocyt
nk
nkt
cell
reduct
tumor
burden
balbc
syngen
renca
model
ovarian
model
cancer
spontan
metastas
abl
reduc
pulmonari
metastasi
spread
lymph
node
dose
either
intratrach
oral
telormedix
clinicalstag
biopharmaceut
compani
propos
divers
prodrug
formul
potent
tlr
agonist
first
gener
repres
liquid
formul
imiquimod
origin
develop
altern
bcg
produc
local
immun
respons
lead
antitumor
activ
circumv
use
live
attenu
mycobacteria
prevent
side
effect
prepar
intraves
instil
imiquimod
develop
urogen
pharma
formerli
theracoat
alreadi
test
pharmacokinet
pharmacodynam
subject
clinic
trial
fig
secondgener
prodrug
conjug
ligand
phospholipid
via
benzoic
acid
function
group
discov
collabor
univers
california
san
diego
alreadi
success
complet
mani
vivo
studi
safe
efficaci
without
caus
excess
advers
effect
could
altern
imiquimod
treatment
prolif
skin
disord
preclin
develop
topic
treatment
skin
cancer
bladder
cancer
indic
respect
fig
pegyl
purinelik
compound
character
partial
agonist
activ
clinic
applic
lung
disord
examin
caution
direct
proinflammatori
effect
seem
addit
promis
candid
adjuv
inactiv
influenza
vaccin
induc
mice
strong
respons
repres
high
level
deriv
contain
glycin
moieti
benzyl
group
similar
induc
nfkb
activ
ifna
secret
express
cell
fig
specif
agonist
activ
even
high
concentr
anoth
base
analogu
commerci
fig
prepar
link
spermin
potent
agonist
induc
nfkb
activ
even
low
concentr
ngml
also
known
fig
deriv
obtain
conjug
bi
phytanyl
phosphon
group
weaker
agonist
contrast
abl
effici
complex
nucleic
acid
result
strong
ifn
respons
compound
abl
form
posit
charg
liposom
encapsul
dna
rna
thank
lipid
moieti
repeat
vivo
studi
show
complex
display
robust
antitumor
activ
tumor
growth
markedli
reduc
result
surviv
rate
notabl
mice
achiev
longterm
clearanc
tumor
follow
treatment
protect
subsequ
tumor
rechalleng
suggest
gener
tumorspecif
memori
immun
respons
also
known
fig
deriv
obtain
linearli
link
hydroxyadenin
deriv
termin
acid
function
agonist
good
ligand
tlr
vivo
tumor
studi
demonstr
potent
antitumor
agent
intratumor
inject
establish
tumor
result
tumor
regress
howev
contrast
protect
tumor
rechalleng
observ
correspond
conjug
hydroxyadenin
deriv
later
chain
second
lysin
result
dual
tlr
agonist
fig
contain
monoacylethylcystein
group
graft
hydroxyadenin
via
glutam
acid
deriv
also
describ
dual
tlr
agonist
fig
among
famili
biggadik
et
al
prepar
deriv
bear
satur
oxygen
nitrogen
heterocycl
substitut
group
treat
allerg
asthma
select
intranas
candid
fig
result
vitro
suppress
cytokin
respons
allergen
vivo
local
upregul
cytokin
clinic
evalu
patient
confirm
pharmacolog
interest
compound
fig
specif
agonist
ec
nm
activ
sever
immun
effector
follow
intraven
administr
nakamura
et
al
demonstr
strong
antitumor
effect
melanoma
lung
metastasi
tumor
mice
model
system
treatment
enhanc
efficaci
radiat
therapi
model
colorect
carcinoma
combin
therapi
ioniz
radiat
gener
antigenspecif
memori
cell
lead
reduct
incid
lung
metastasi
improv
surviv
kht
fibrosarcoma
model
confirm
effect
mous
renal
cell
carcinoma
model
kogayamakawa
et
al
also
show
dose
schedul
system
administ
agonist
significantli
affect
tlr
toler
antitumor
activ
offer
potenti
solut
overcom
tlr
toler
fig
agonist
lead
induct
ifnag
tnfa
intraven
inject
reduct
tumor
burden
syngen
model
renal
cancer
renca
metastat
osteosarcoma
colorect
cancer
moreov
efficaci
significantli
improv
administ
combin
lowdos
fraction
radiotherapi
longterm
surviv
mice
origin
treat
radiotherapi
protect
tumorspecif
memori
immun
respons
could
prevent
tumor
growth
previou
work
show
vitro
nfkb
activ
immunomodul
agent
could
link
vivo
observ
loxoribin
fig
display
interest
antitumor
activ
signific
inhibit
melanoma
lung
tumor
metastasi
observ
mice
receiv
singl
inject
mg
loxoribin
day
tumor
growth
greatest
inhibit
correspond
four
inject
loxoribin
altern
day
start
day
tumor
inject
combin
loxoribin
significantli
greater
inhibit
metastasi
guanosin
analogu
display
adjuv
activ
b
cell
system
loxoribin
evalu
adjuv
tumor
protect
model
mice
immun
irradi
tumor
cell
loxoribin
develop
significantli
lower
number
lung
tumor
challeng
live
tumor
cell
wherea
mice
inject
either
vaccin
loxoribin
alon
protect
loxoribin
also
test
treatment
chronic
lymphocyt
leukemia
way
loxoribin
may
use
tumor
therapi
immunomodul
adjuv
isatoribin
fig
synthesi
describ
nagahara
et
al
enhanc
ifna
level
interact
stimul
patient
immun
system
potent
toxic
profil
multipl
speci
compound
display
antivir
activ
varieti
murin
system
semliki
forest
san
angelo
banzi
ratcorona
emc
virus
moder
absent
antivir
effect
observ
vsv
infect
influenza
b
pneumonia
isatoribin
also
evalu
chronic
hepat
c
infect
pyridin
compound
incorpor
substitu
previous
determin
optim
agonist
fig
imidazoquinolin
seri
compound
studi
potenc
induc
ifna
product
compound
show
agonist
activ
mm
neglig
activ
direct
arylaryl
bond
posit
abolish
activ
agonist
effect
restor
analogu
benzyl
phenethyl
group
exampl
specif
agonist
compound
mm
display
high
ifna
induct
human
pbmc
sinc
compound
potent
induc
type
ifn
attenu
proinflammatori
profil
could
potent
adjuv
without
local
system
inflamm
reaction
quest
new
vaccin
adjuv
beesu
et
al
synthes
wide
varieti
heterocycl
compound
show
good
select
compound
fig
selgantolimod
also
known
fig
agonist
induc
cellular
immun
mediat
well
antivir
cytokin
tnfa
ifng
vitro
human
pbmc
selgantolimod
activ
nk
mucos
associ
invari
cell
stimul
cluster
differenti
cd
tcell
prolifer
lower
program
cell
death
protein
express
hbvspecif
cell
vitro
selgantolimodinduc
cytokin
reduc
hbv
dna
rna
antigen
level
hbvinfect
primari
human
hepatocyt
agonist
actual
investig
treat
hiv
infect
hepat
b
viru
satur
deriv
pteridinonebas
compound
identifi
potent
select
agonist
lead
discoveri
also
known
vesatolimod
fig
drug
multipl
potent
applic
oral
furthermor
could
activ
signal
immun
cell
induc
clearanc
viru
infect
cell
minimum
effect
concentr
ifna
induct
similar
pdc
pbmc
hcvposit
donor
shown
stimul
immun
respons
differ
anim
model
chronic
hepat
b
infect
mice
woodchuck
nonhuman
primat
administ
hbv
infect
three
chimpanze
week
interv
week
consequ
serum
concentr
hbv
surfac
antigen
hbv
antigen
number
hbv
antigeneposit
hepatocyt
decreas
hepatocyt
apoptosi
increas
phase
clinic
trial
evalu
safeti
toler
treatment
result
dose
depend
increas
select
cytokin
chemokin
isg
begin
mg
safe
singl
dose
mg
increas
percentag
immunocyt
like
cell
b
cell
nk
cell
express
also
note
subject
receiv
treatment
dosedepend
pharmacodynam
induct
interferonstimul
gene
isg
demonstr
without
signific
system
induct
ifna
express
relat
symptom
signific
hepat
b
surfac
antigen
declin
observ
moreov
abl
vitro
inhibit
infect
human
peripher
blood
mononuclear
cell
also
demonstr
induc
hiv
rna
express
ex
vivo
pbmc
isol
patient
suppress
antiretrovir
therapi
although
inact
hiv
purifi
cell
macrophag
hiv
replic
potent
inhibit
condit
medium
deriv
pdc
cultur
ad
cell
prior
infect
pbmc
primarili
show
increas
product
ifna
cotreat
ifnablock
antibodi
revers
effect
supplementari
studi
demonstr
inhibit
postentri
event
hiv
replic
step
coincid
prior
revers
transcript
induc
phagocyt
cell
matur
improv
effectormedi
kill
hivinfect
cell
hiv
envelopespecif
broadli
neutral
antibodi
data
show
compound
enhanc
antibodymedi
clearanc
hivinfect
cell
improv
immun
effector
function
target
specif
cell
clinic
evalu
reduc
latent
reservoir
viral
suppress
hivinfect
patient
viral
reservoir
latent
infect
cell
respons
viral
rebound
vast
major
individu
stop
take
antiretrovir
therapi
key
challeng
cure
infect
repres
extens
studi
therapeut
strategi
known
shock
kill
strategi
aim
toward
reactiv
latent
reservoir
use
latencyrevers
agent
lra
subsequ
kill
reactiv
cell
either
cytotox
arm
immun
system
includ
nk
cell
viral
cytopath
mechan
borducchi
et
al
show
administr
glycandepend
bnab
togeth
art
delay
viral
rebound
follow
discontinu
art
simianehuman
immunodefici
viru
shiv
rhesu
monkey
art
initi
earli
acut
infect
contrast
result
obtain
del
prete
et
al
anoth
structurallyunpublish
agonist
also
evalu
reduc
latent
reservoir
sivinfect
rhesu
monkey
among
panel
tetrahydropyridopyrimidin
macgowan
et
al
identifi
potent
dual
tlr
agonist
least
effect
concentr
mm
mm
fig
demonstr
induct
interferong
induc
protein
pharmacokinet
profil
mice
confirm
low
system
exposur
addit
show
low
plasma
protein
bind
bound
mice
plasma
inhibit
major
isozym
mm
lack
offtarget
activ
across
multireceptor
panel
mm
histamin
dopamin
serotonin
subtyp
also
known
pluripotin
fig
agonist
inhibitor
extracellular
signalregul
kinas
rasgap
kd
valu
nm
nm
respect
maintain
embryon
stem
cell
selfrenew
absenc
feeder
cell
exogen
factor
longterm
murin
embryon
stem
cell
differenti
cell
three
primari
germ
layer
vitro
also
gener
chimer
mice
contribut
germ
line
vivo
intraven
administ
mediat
system
releas
type
ifn
proinflammatori
cytokin
tnfa
result
activ
circul
immun
cell
intratumor
cell
significantli
increas
pdc
strongli
activ
macrophag
phenotyp
polar
wherea
myeloidderiv
suppressor
cell
decreas
prevent
spontan
lung
metastasi
retard
tumor
growth
result
tumor
reject
prolong
surviv
importantli
protect
tumor
rechalleng
demonstr
vascotto
et
al
melanoma
colorect
cancer
tumor
model
treatment
mice
inhibit
growth
establish
syngen
tumor
result
significantli
prolong
surviv
tumorfre
mice
treat
protect
subsequ
tumor
rechalleng
also
effici
prevent
lung
metastas
pulmonari
metastat
renca
model
mice
bear
nk
cellsensit
lymphoma
rma
cure
repeat
c
administr
effici
resiquimod
relev
toxic
observ
mechanist
revers
nk
cell
anergi
restor
nk
cellmedi
tumor
cell
kill
ifndepend
manner
unpublish
structur
dualspecif
tlr
agonist
display
pronounc
proinflammatori
cytokin
releas
addit
experi
show
signific
upregul
activ
marker
nk
cell
increas
cytolyt
activ
peripher
blood
cell
fig
select
potent
benzazepin
small
molecul
agonist
tlr
ec
nm
display
select
coordin
activ
activ
nk
cell
augment
adcc
treat
stimul
tnfa
product
lower
concentr
human
pbmc
also
induc
tnfa
secret
monocyt
myeloid
dc
nfkb
pathway
ifng
secret
observ
nk
cell
treat
enhanc
lytic
capabl
antibodydepend
cellmedi
cytotox
nk
cell
also
improv
efficaci
pegyl
liposom
doxorubicin
treatment
ovarian
cancer
mous
model
human
immun
system
reconstitut
human
cell
compound
evalu
treatment
varieti
cancer
includ
head
neck
cancer
colorect
pancreat
melanoma
breast
renal
cell
carcinoma
non
smallecel
lung
carcinoma
solid
neoplasm
evalu
standalon
drug
treatment
lymphoma
essenti
use
combin
drug
thank
potenti
immunostimul
anticanc
activ
current
clinic
develop
immunotherapi
multipl
oncolog
indic
ovarian
cancer
squamou
cell
carcinoma
head
neck
intranas
formul
phase
clinic
trial
allerg
rhiniti
among
vtx
famili
fig
also
known
defin
ultrapot
agonist
activ
newborn
adult
leukocyt
candid
vaccin
adjuv
earli
life
adulthood
activ
hek
cell
nm
vs
nm
defin
way
select
tnf
product
compar
newborn
cord
adult
peripher
blood
potent
mpla
combin
mpla
induc
greater
blood
tnf
respons
combin
mpla
also
potent
induc
express
cytokin
costimulatori
molecul
hladr
human
newborn
modc
anoth
agonist
preclin
studi
treat
autoimmun
inflamm
dual
tlr
agonist
preclin
studi
treat
allergi
benzoazepin
analogu
motolimod
fig
also
ligand
potent
resiquimod
activ
helblu
cell
nm
vs
mm
potent
induc
nfkb
activ
cell
resiquimod
nm
vs
nm
nm
respect
quinolin
seri
imiquimod
deriv
resiquimod
fig
first
synthet
molecul
describ
literatur
andor
agonist
variou
deriv
design
imiquimod
also
known
fig
tricycl
nitrogen
molecul
belong
imidazo
quinolin
seri
develop
pharmaceut
laboratori
saint
paul
mn
usa
commerci
respect
imiquimodcontain
cream
first
describ
antivir
activ
certain
virus
herp
simplex
ii
hsvii
sendai
viru
papilloma
viru
molecul
directli
inhibit
viral
replic
immunomodul
whose
viral
activ
relat
induc
power
ifna
cytokin
approv
food
drug
administr
fda
treatment
extern
genit
perian
wart
condylomata
acuminata
use
extend
treatment
actin
keratosi
superfici
basal
cell
carcinoma
hemmi
et
al
shown
imiquimod
deriv
resiquimod
fig
exert
antivir
antitumor
properti
via
mm
show
mice
abl
produc
proinflammatori
cytokin
follow
stimul
imiquimod
resiquimod
bound
receptor
imiquimod
trigger
signal
pathway
drive
activ
nfkb
activ
nfkb
migrat
nucleu
induc
transcript
proinflammatori
cytokin
tnfa
well
ifna
consequ
effect
mark
stimul
immun
respons
infect
tumor
cell
effect
imiquimod
also
demonstr
skin
recruit
activ
pdc
addit
topic
appli
imiquimod
induc
matur
epiderm
langerhan
cell
vivo
stimul
migrat
antigenpres
cell
lymph
node
induc
specif
tcell
respons
addit
imiquimod
also
enhanc
adapt
immun
indirectli
stimul
product
ifng
cytokin
involv
respons
high
concentr
imiquimod
induc
apoptosi
tumor
cell
via
activ
protein
caspas
famili
besid
fda
approv
indic
topic
imiquimod
use
treatment
sever
infecti
skin
disord
nonanagenit
cutan
wart
molluscum
contagiosum
cutan
leishmaniasi
etc
neoplast
fungoid
mycosi
vascular
tumor
cutan
metastas
etc
disord
ring
granuloma
primari
follicular
mucinosi
moreov
topic
imiquimod
might
consid
adjuv
vaccin
imiquimod
also
test
potent
agent
prostat
bladder
breast
cancer
squamou
carcinoma
resiquimod
also
known
fig
imidazo
quinolin
compound
stimul
immun
system
activ
mm
mm
develop
pharmaceut
laboratori
earli
attempt
identifi
nucleosidelik
structur
inhibit
infect
although
imiquimod
deriv
resiquimod
belong
chemic
famili
resiquimod
activ
wherea
imiquimod
agonist
differ
tlr
bind
presum
explain
import
cytokin
induct
subsequ
tlr
activ
cytokin
profil
observ
follow
exposur
human
pbmc
resiquimod
similar
imiquimod
nevertheless
level
express
proinflammatori
cytokin
tnfa
well
ifna
approxim
time
higher
use
resiquimod
compar
imiquimod
respons
resiquimod
dendrit
cell
secret
tnfa
ifna
monocyt
secret
tnfa
ifna
even
develop
topic
resiquimod
treatment
genit
herp
human
discontinu
due
inconsist
result
clinic
trial
mani
studi
shown
interest
resiquimod
treatment
cutan
tumor
resiquimod
consid
potenti
treatment
due
lack
efficaci
clinic
trial
develop
indic
stop
nevertheless
compound
prove
effect
treatment
actin
keratosi
skin
level
target
cell
resiquimod
mainli
monocyt
dendrit
cell
pdc
express
mdc
express
tlr
therefor
resiquimod
stimul
tlr
tlr
induc
strong
cytokin
respons
includ
typei
ifn
proinflammatori
cytokin
may
explain
antitumor
effect
resiquimod
skin
cancer
basal
cell
carcinoma
bcc
tumor
cell
imiquimod
show
direct
independ
death
receptor
bind
proapoptot
activ
activ
also
observ
resiquimod
howev
much
smaller
extent
compar
imiquimod
resiquimod
indirectli
provok
apoptosi
induct
tumor
cell
induc
express
trail
tnfrelat
apoptosisinduc
ligand
dendrit
cell
thu
increas
cytotox
potenc
rook
et
al
shown
topic
resiquimod
also
improv
effector
cell
function
cutan
tcell
lymphoma
consequ
induc
regress
diseas
furthermor
resiquimod
proven
effect
adjuv
sever
diseas
cancer
given
abil
induc
local
activ
immun
cell
stimul
product
proinflammatori
cytokin
improv
present
antigen
dendrit
cell
lead
activ
cellular
immun
respons
like
cytotox
lymphocyt
resiquimod
also
test
potent
agent
glioma
acut
myeloid
leukemia
presenc
alkyl
hydroxyalkyl
chain
r
posit
substitut
r
show
good
ifn
induct
human
pbmc
fig
howev
activ
improv
compar
unsubstitut
compound
r
longer
alkyl
chain
heptyl
bulkier
alkyl
substitu
ie
tertbutyl
consid
r
activ
abolish
activ
also
lost
phenyl
group
directli
link
r
posit
substitut
alkyl
group
r
posit
improv
ifn
induct
small
chain
butyl
bring
better
activ
mec
mgml
mgml
butyl
pentyl
respect
phenoxymethyl
benzyl
group
r
also
increas
activ
amin
posit
essenti
activ
modif
posit
rule
ifn
product
overal
simpl
substitut
benzen
ring
appear
detriment
sinc
synthes
compound
effici
induc
ifn
howev
compound
preserv
activ
unsubstitut
scaffold
among
tlr
ligand
commerci
watersolubl
imidazoquinolin
deriv
similarli
resiquimod
agonist
fig
induc
activ
nfkb
mm
transfect
cell
mm
cell
also
induc
proinflammatori
cytokin
macrophag
gorden
et
al
studi
select
toward
compound
belong
imidazo
quinolin
thiazolo
quinolin
seri
fig
compound
select
agonist
respect
compound
also
known
fig
use
preclin
studi
ovarian
cervix
breast
cancer
undergon
clinic
trial
melanoma
phase
ii
lymphocyt
leukemia
phase
iii
compound
also
known
fig
low
water
solubl
highli
potent
immunostimul
system
toxic
polymersom
nanocarri
encapsul
mimick
immunomodulatori
effect
live
bcg
vaccin
improv
innat
adapt
neonat
immun
respons
vitro
immunostimulatori
activ
human
newborn
adult
monocytederiv
dendrit
cell
modc
benchmark
convent
adjuv
human
vaccin
includ
live
attenu
bcg
vaccin
elicit
moder
immun
neonat
safe
effect
birth
compar
bcg
induc
greater
product
cytokin
enhanc
immun
respons
promot
cytotox
tcell
prolifer
surviv
consid
result
dow
et
al
suggest
strong
potenti
serv
dual
antigenadjuv
vaccin
deliveri
system
human
neonat
vaccin
compound
agonist
fig
structur
famili
fig
describ
potent
tlr
agonist
stimul
type
ifn
cytokin
tnfa
ifng
rat
peripher
blood
mononuclear
cell
induc
express
mdc
hivindividu
inhibit
influenza
viral
replic
nasal
caviti
potenti
nk
cytotox
show
antitumor
effect
mice
scidnod
mice
evalu
pancreat
gastrointestin
colon
cancer
also
bladder
renal
cancer
also
known
telratolimod
fig
inject
tlr
agonist
correspond
lipid
modifi
imidazoquinolin
abl
form
tissu
depot
gradual
sustain
releas
allow
local
tlr
trigger
activ
without
system
cytokin
releas
final
modifi
tumor
microenviron
display
potenti
immunostimul
antitumor
activ
compound
use
potent
agent
melanoma
studi
even
retain
sight
inject
limit
system
exposur
upon
intratumor
administr
also
gener
system
antitumor
immun
agonist
abl
suppress
inject
distant
uninject
wildtyp
poorli
immunogen
melanoma
mice
also
immunogen
version
melanoma
treat
tumor
show
increas
level
chemokin
infiltr
phenotypeshift
macrophag
could
kill
tumor
cell
directli
product
nitric
oxid
therapi
potenti
checkpoint
blockad
therapi
antibodi
also
confirm
mullin
et
al
zhao
et
al
show
combin
cpg
odn
increas
cytotox
cell
activ
cytokin
product
downregul
activ
immunosuppress
myeloid
deriv
suppressor
cell
combin
allow
tumor
suppress
colon
cancer
bear
mice
establish
longterm
immun
hoeven
et
al
describ
formul
develop
studi
hydrophob
allow
incorpor
lipidbas
formul
anion
cation
pegyl
neutral
liposom
oilinwat
emuls
abl
protect
mice
ferret
infect
caus
lethal
homolog
viru
furthermor
demonstr
abil
adjuv
formul
broaden
respons
hemagglutininbas
antigen
gardiquimod
fig
agonist
human
although
activ
porcin
enhanc
immunosuppress
activ
regulatori
cell
mgml
gardiquimod
effect
mucos
adjuv
norwalk
viruslik
particl
inhibit
infect
macrophag
cell
inhibit
prolifer
migrat
induc
apoptosi
pancreat
cancer
cell
vitro
guardiquimod
also
evalu
melanoma
note
gardiquimod
activ
agonist
imiquimod
base
data
shukla
et
al
hypothes
ethylaminomethylen
substitu
gardiquimod
bring
suffici
polar
prevent
effici
transcutan
penetr
stimul
plasmacytoid
dendrit
cell
hydrophob
analogu
gardiquimod
later
synthes
agonist
activ
studi
use
cell
express
either
compound
modif
secondari
amin
posit
conveni
keep
agonist
activ
replac
imidazol
ring
triazol
ring
lead
total
loss
activ
group
absolut
necessari
obtain
maximum
activ
seri
synthes
lipophil
compound
carri
benzyl
group
posit
alkyl
chain
show
link
length
alkyl
chain
agonist
activ
optim
activ
observ
compound
carri
butyl
chain
fig
minimum
effect
concentr
ifn
induct
observ
mgml
suggest
gerster
et
al
rearrang
substitu
gardiquimod
compound
lead
identif
highli
activ
compound
agonist
ec
nm
fig
compound
select
without
agonist
activ
shi
et
al
synthes
imidazo
quinolin
seri
replac
hydrogen
carbon
methoxycarbonyl
group
fig
show
elimin
ethoxymethyl
chain
resiquimod
result
signific
decreas
agonist
activ
complet
loss
agonist
activ
activ
restor
even
improv
addit
butyl
chain
posit
mm
mm
unsubstitut
posit
carri
methoxycarbonyl
group
posit
compound
lack
tlr
agonist
activ
howev
abl
induc
high
product
proinflammatori
cytokin
tnfa
suggest
exist
altern
mechan
action
imidazoquinolin
stimul
product
cytokin
addit
alkyl
butyl
chain
posit
restor
agonist
activ
indic
substitut
may
import
cytokin
product
wherea
tlr
agonist
activ
requir
substitut
base
data
schiaffo
et
al
synthes
imidazo
quinolin
introduc
substitu
posit
fig
result
show
tlr
agonist
activ
correl
length
alkyl
chain
posit
maximum
tlr
activ
deriv
butyl
activ
pentyl
similar
sar
studi
also
identifi
product
ifng
depend
length
alkyl
chain
substitut
compound
also
stimul
product
ifna
less
pronounc
structur
correl
larson
et
al
propos
imidazo
quinolin
deriv
substitut
posit
agonist
fig
select
compound
obtain
introduct
ethyl
propyl
butylamino
group
posit
analysi
sar
indic
activ
less
sensit
modif
howev
high
affin
obtain
extend
aminoalkyl
chain
length
pentyl
p
fig
fig
analog
fig
synthes
alkylthiazoloquinolin
methyl
ethyl
propyl
butyl
group
posit
compar
agonist
activ
activ
moder
decreas
pentylbear
compound
posit
complet
lost
compound
longer
alkyl
chain
virtual
chang
posit
led
loss
agonist
activ
alkyl
amin
posit
toler
compound
butyl
also
endow
agonist
activ
immun
rabbit
antigen
adjuv
compound
show
signific
improv
antigenspecif
antibodi
titer
given
pledg
agonist
product
proinflammatori
cytokin
includ
tnfa
activ
respons
neonat
antigen
present
cell
research
focus
synthesi
select
agonist
use
vaccin
adjuv
particular
improv
immun
respons
newborn
furo
quinolin
well
alkyl
aminoquinolin
synthes
kokatla
et
al
evalu
agonist
activ
fig
fig
imidazo
quinoxalin
show
select
toward
ec
mm
activ
confirm
studi
secret
cytokin
human
pbmc
compound
show
abil
produc
ifna
wherea
compound
agonist
abl
produc
addit
compound
abl
produc
proinflammatori
cytokin
tnfa
type
ii
interferon
ifng
well
chemokin
dock
studi
perform
activ
compound
ectodomain
human
agonist
belong
novarti
global
pipelin
defin
antineoplast
agent
fig
mice
induc
immun
respons
reduc
tumor
growth
show
sign
abscop
effect
current
evalu
patient
advanc
malign
either
singl
agent
combin
checkpoint
inhibitor
thymidin
homopolym
phosphorothio
odn
commerci
describ
modul
human
tlr
fig
poli
dt
alon
signific
effect
tlr
nevertheless
combin
imidazoquinolin
resiquimod
poli
dt
increas
mediat
signal
abolish
mediat
signal
moreov
coincub
poli
dt
imidazoquinolin
induc
nfkb
activ
cell
transfect
murin
primari
mouss
cell
rnabas
agonist
develop
multicel
technolog
inc
high
molecular
weight
synthet
doublestrand
rna
dsrna
design
activ
innat
immun
system
tlr
signal
immun
enhanc
properti
preclin
studi
success
reduc
pulmonari
influenza
viru
level
anim
model
also
demonstr
effect
reduc
viru
level
hiv
hcv
anim
model
current
ongo
preclin
trial
liver
cancer
hepatocellular
carcinoma
breast
cancer
tripleneg
breast
cancer
tnbc
other
accord
compani
could
indic
cancer
adjuv
therapi
alon
combin
current
avail
novel
therapi
also
combin
patent
pend
antigenpres
immunoglobulin
therapeut
treatment
variou
cancer
breast
metastat
colorect
carcinoma
ssrnabas
tlr
retino
acidinduc
gene
rigi
agonist
contain
noncod
uncap
sever
polyurepeat
complex
polymer
carrier
form
argininerich
disulfidecrosslink
cation
peptid
develop
curevac
compani
adjuv
enhanc
immunogen
poorli
immunogen
antigen
upon
intratumor
inject
stimul
respons
activ
system
cytotox
tlymphocytemedi
immun
respons
tumor
cell
simultan
expos
tumorassoci
antigen
actual
clinic
investig
oncolog
indic
research
develop
agonist
ligand
clearli
boom
certain
referenc
product
display
interest
activ
without
detail
chemic
structur
indic
belong
chemic
famili
sometim
given
tabl
besid
role
defens
tool
immun
system
overactiv
dysregul
tlr
signal
caus
panel
diseas
tlr
today
well
known
implic
develop
autoimmun
diseas
cancer
progress
acquir
immunodefici
syndrom
aid
counter
uncontrol
tlrmediat
signal
major
subject
research
last
decad
design
tlr
agonist
ligand
much
lesser
extent
tlr
antagonist
ligand
tlr
antagonist
regul
inhibit
reduc
activ
tlrmediat
cytokin
cascad
check
overreact
uncontrol
adapt
immun
respons
tlr
antagonist
gener
modifi
agonist
bind
tlr
fail
induc
signal
transduct
recent
highlight
exist
antagonist
pocket
tlr
also
allow
specif
structurebas
design
use
molecular
model
tool
produc
new
potent
structur
repres
novel
therapi
treat
prevent
diseas
cite
herein
scientif
literatur
show
autoimmun
diseas
lupu
psoriasi
tlr
recogn
endogen
immun
complex
ic
contain
nucleic
acid
induc
proinflammatori
cytokin
contribut
progress
diseas
tlr
activ
ic
lead
tnfa
ifna
express
associ
presenc
antidna
antirna
autoantibodi
patient
system
lupu
erythematosu
sle
autoantibodi
caus
organ
damag
bind
directli
host
tissu
form
ic
deposit
vascular
tissu
therebi
induc
destruct
inflamm
sever
studi
use
tlrdefici
mice
investig
role
tlr
develop
sle
mice
prone
lupu
delet
mice
prone
lupu
led
failur
antibodi
product
decreas
lymphocyt
activ
decreas
serum
igg
level
attenu
diseas
role
autoimmun
diseas
extens
studi
perhap
lack
respons
ligand
murin
model
differ
respons
immun
profil
tlr
stimul
respons
character
high
product
type
ifn
ifna
appear
play
major
role
autoimmun
diseas
stimul
low
level
ifna
induc
strong
product
proinflammatori
cytokin
howev
tnfa
produc
activ
may
exert
proinflammatori
effect
autoimmun
diseas
stimul
ribonucleoprotein
mrna
overregul
patient
ogren
syndrom
indic
possibl
role
autoimmun
process
psoriasi
chronic
autoimmun
inflammatori
diseas
skin
extracellular
rna
form
complex
cation
antimicrobi
peptid
complex
highli
protect
degrad
rna
access
endosom
compart
pdc
mdc
complex
induc
activ
pdc
trigger
ifna
secret
complex
also
trigger
direct
activ
mdc
secret
tnfa
differenti
matur
dendrit
cell
matur
mdc
trigger
endosom
enhanc
concomit
activ
pdc
produc
ifna
data
identifi
complex
endogen
trigger
human
dendrit
cell
thu
lead
develop
psoriasi
contrast
therapeut
benefit
tlr
agonist
immun
cell
sever
studi
shown
tlr
stimul
promot
tumor
progress
cherfilsvicini
et
al
shown
highli
express
primari
tumor
cell
patient
nonsmal
cell
lung
cancer
nsclc
addit
chemoresist
patient
nsclc
agonist
induc
import
protumurogen
effect
vitro
effect
also
verifi
immunodefici
nodscid
immunocompet
murin
model
use
subcutan
graft
lung
carcinoma
cell
model
repeat
administr
agonist
loxoribin
imiquimod
result
increas
tumor
volum
protumorigen
effect
could
mediat
direct
stimul
tumor
cell
express
increas
recruit
differenti
immunosuppress
cell
tumor
microenviron
furthermor
research
team
find
similar
result
variou
tumor
model
stimul
pancreat
cancer
model
express
induc
tumor
growth
acceler
reduct
antitumor
molecul
express
similarli
stimul
hepatocellular
carcinoma
model
express
boost
malign
cell
prolifer
chronic
immun
activ
lead
caus
progress
immunodefici
human
immunodefici
viru
type
infect
hiv
ssrna
potent
immun
activ
trigger
signal
hiv
viru
directli
contribut
activ
immun
system
dysfunct
stimul
recent
studi
shown
activ
human
cell
trigger
anerg
state
may
contribut
cell
hyporeact
infect
may
also
increas
spread
viru
unexpect
role
whose
activ
facilit
infect
cell
block
use
inhibitor
presenc
inhibitor
led
attenu
infect
author
conclud
use
anerg
state
induc
activ
support
spread
inhibit
tlr
activ
synthet
compound
therefor
promis
research
area
potenti
treatment
autoimmun
diseas
cancer
aid
tlr
antagonist
bind
receptor
inhibit
activ
therebi
suppress
inher
immun
respons
till
antagonist
molecul
compound
develop
gener
structur
analogu
tlr
agonist
case
agonist
current
known
antagonist
divid
two
group
oligonucleotid
biand
tricycl
heterocycl
compound
discu
search
agonist
contain
benzimidazol
moieti
beesu
et
al
prepar
inact
agonist
fig
competit
inhibit
inhibit
tlr
unknown
mechan
micromolar
affin
pantlr
antagonist
toward
multipl
tlr
variou
cell
line
suggest
could
promis
antiinflammatori
agent
kinasescreen
compound
show
rel
specif
calmodulin
kinas
recent
zhang
et
al
identifi
first
time
human
small
antagonist
molecul
novel
inhibit
mechan
sar
studi
pyrazolo
pyrimidin
seri
led
identif
compound
prove
activ
nm
strong
abil
inhibit
product
proinflammatori
cytokin
fig
dock
studi
reveal
sandwich
two
monom
local
hydrophob
pocket
proteinprotein
interfac
two
monom
new
bind
site
close
distinct
identifi
agonist
site
whose
occup
prevent
activ
impli
new
inhibitori
mechan
encourag
result
author
carri
structur
optim
led
two
new
inhibitor
belong
quinolin
seri
structur
similar
nm
nm
fig
block
newli
identifi
site
inhibitor
appear
antagon
bind
agonist
uridin
andor
block
conform
chang
necessari
receptor
activ
addit
author
explor
effect
human
sampl
variou
patient
inflammatori
autoimmun
diseas
studi
show
treatment
potent
antiinflammatori
effect
sampl
patient
osteoarthr
oa
rheumatoid
arthriti
ra
adult
still
diseas
thu
confirm
previous
publish
work
show
may
play
role
inflammatori
disord
autoimmun
diseas
known
antimalari
drug
chloroquin
cq
hydroxychloroquin
hcq
fig
use
treat
autoimmun
diseas
arthriti
sle
world
war
ii
weak
base
tend
accumul
acid
intracellular
compart
endosom
lysosom
modul
ph
lead
suppress
autoantigen
present
blockad
endosom
tlr
signal
decreas
cytokin
product
mechan
includ
inhibit
mapk
signal
phospholipas
antiprolifer
photoprotect
well
reduct
matrix
activ
mechan
action
highlight
antiinflammatori
immunosuppress
activ
antimalari
drug
act
endosom
tlr
signal
tlr
moreov
cq
investig
diseas
associ
uncontrol
acut
chronic
inflamm
sever
sepsi
prevent
treat
viral
infect
hiv
influenza
dengu
cardiovascular
diseas
cancer
notabl
modul
autophagi
long
term
hcq
administr
amelior
hypertens
aortic
endotheli
dysfunct
sle
mous
model
quinazolin
deriv
coley
pharmaceut
group
inc
fig
tlr
antagonist
tlr
ratio
inhibit
diseas
progress
sle
rheumatoid
arthriti
autoimmun
diseas
anim
model
also
increas
potenc
compar
hcq
alon
combin
therapi
ad
efficaci
prevent
format
antidna
antibodi
slepron
mice
evalu
phase
clinic
trial
sle
therapi
shukla
et
al
synthes
gardiquimod
agonist
regioisom
order
explor
sar
substitu
imidazolin
ring
fig
compound
reveal
complet
inact
agonist
surprisingli
weak
antagonist
effect
desamino
precursor
potent
antagonist
mm
among
synthes
compound
quinolinium
bear
pmethoxybenzyl
substitu
posit
identifi
activ
antagonist
ic
mm
mm
respect
fig
compound
carri
propargyl
group
also
shown
good
tlr
antagonist
activ
mm
rang
may
prove
use
support
addit
alkyl
posit
electronrich
substitu
compound
dimer
link
posit
also
evalu
link
dimer
agonist
dimer
spacer
carbon
atom
doubl
agonist
dimer
propylen
spacer
maxim
antagonist
mm
respect
fig
compound
also
show
inhibit
proinflammatori
cytokin
product
human
pbmc
recent
deleuzemasqu
efa
et
al
synthes
character
varieti
compound
belong
three
heterocycl
chemic
seri
imidazo
pyrazin
imidazo
quinoxalin
pyrazolo
quinoxalin
compound
test
agonist
antagonist
activ
sever
shown
select
antagonist
without
agonist
activ
select
confirm
compar
liganddock
studi
suggest
specif
bind
mode
novel
antagonist
site
two
compound
pyrazolo
quinoxalin
seri
tlr
antagonist
watersolubl
analog
artemisinin
use
antimalari
drug
fig
possess
better
bioavail
better
immunosuppress
activ
tradit
arteminisin
deriv
display
antiprolif
antiinflammatori
properti
vitro
inhibit
ifng
product
polyclon
cell
activ
cell
receptor
engag
differenti
naiv
cell
cell
treg
cell
ex
vivo
treatment
elev
percentag
treg
cell
imped
comprehens
activ
protein
splenocyt
suppress
tlrtrigger
activ
prolifer
b
cell
well
antibodi
secret
interf
bcell
intrins
pathway
downregul
tlr
mrna
express
protein
express
nfkb
phosphoryl
studi
shown
therapeut
effect
oral
administ
lupuspron
mrllpr
mice
inhibit
cell
respons
suppress
b
cell
activ
plasma
cell
product
amelior
proteinurea
renal
lesion
sever
exhibit
protect
effect
two
mous
model
sle
mrllpr
nzbw
mice
suppress
pathogen
tcell
develop
murin
model
multipl
sclerosi
eae
abl
stop
progress
revers
clinic
histopatholog
sign
via
modul
balanc
cell
subset
especi
promot
treg
cell
gener
collageninduc
arthriti
mice
amelior
sever
arthriti
inhibit
develop
tfh
cell
well
autoantibodi
product
could
prohibit
signal
pathway
prevent
activ
target
differ
domain
tlr
could
block
activ
inhibit
could
also
done
indirectli
target
effector
relationship
tlr
part
explicit
due
remot
main
research
fig
fig
abl
interact
nucleic
acid
dna
rna
agonist
acid
intracellular
compart
oral
bioavail
compound
inhibit
shortterm
induct
inflammatori
cytokin
dna
mous
mrllpr
spontan
model
lupu
slow
develop
circul
antinuclear
antibodi
modestli
suppress
antidsdna
observ
impact
proteinuria
mortal
effect
prevent
hyperinflamm
lethal
caus
parasit
plasmodium
berghei
mous
model
cerebr
malaria
evalu
sle
autoimmun
diseas
piao
al
found
peptid
pqrfcklrkimnt
sequenc
deriv
helix
tir
domain
specif
target
tirap
block
tlr
tnfa
signal
confirm
vitro
studi
cell
imag
coimmunoprecipit
bind
tirap
nanomolar
affin
result
fast
associ
rate
coupl
slow
dissoci
complex
bind
albumin
micromolar
affin
diminish
system
cytokin
respons
elicit
vivo
synthet
agonist
inhibit
activ
macrophag
infect
influenza
strain
significantli
improv
surviv
mice
thu
repres
tlrtarget
agent
block
protein
interact
downstream
activ
tlr
judg
et
al
shown
incorpor
omethyl
ome
uridin
omeguanosin
residu
sirna
ssrna
elimin
immunostimulatori
activ
vitro
vivo
also
report
chemic
modif
nucleotid
mammalian
rna
includ
ome
modif
prevent
activ
dendrit
cell
robbin
et
al
test
abil
ome
rna
antagon
immun
stimul
report
ome
rna
directli
inhibit
cytokin
induct
murin
human
system
immunostimulatori
rna
agonist
loxoribin
inhibitori
activ
ome
rna
also
shown
vivo
result
indic
ome
rna
act
antagonist
antimirna
target
tlr
bind
viral
bacteri
infect
oligodeoxynucleotid
odn
contain
unmethyl
cpg
dinucleotid
act
agonist
induc
type
immun
respons
hand
substitut
cytosin
cpg
motif
omethylcytosin
substitut
guanosin
omethylguanosin
lead
loss
immunostimulatori
activ
oligonucleotid
therefor
appear
antagonist
dynavax
technolog
design
immunoregulatori
oligonucleotid
iro
omethyl
methoxyethyl
sugar
modif
inhibitor
andor
dynavax
technolog
develop
iro
uniqu
inhibitori
sequenc
suppress
autoimmun
inflammatori
diseas
novel
approach
appli
treat
varieti
autoimmun
diseas
sle
cutan
lupu
erythematosu
cle
system
sclerosi
polymyos
dermatomyos
ra
sjorgren
syndrom
base
work
sever
recent
studi
focus
synthesi
oligonucleotid
use
chemic
modif
mention
idera
pharmaceut
design
uniqu
cpg
oligonucleotid
sequenc
contain
immun
stimulatori
motif
arabinog
modif
immun
regulatori
motif
omethylribonucleotid
act
antagonist
tlr
iro
shown
promis
result
preclin
studi
effect
prevent
hyperactiv
tlr
respons
agonist
foreseen
futur
therapi
tlr
inflammatori
disord
includ
variou
autoimmun
inflammatori
diseas
cancer
initi
pathogen
chemic
modif
andor
internucleotid
linkag
introduc
iro
found
increas
inhibit
suppress
tlr
leader
also
known
bazlitoran
sequenc
ctatctnnnnttctctnn
oligonucleotid
antagonist
current
clinic
develop
phase
iia
treatment
plaqu
psoriasi
dermatomyos
treatment
antagonist
regul
gene
express
demonstr
suarezfarina
et
al
compound
effect
prevent
inflamm
diseas
develop
lupu
psoriasi
mous
model
similar
tlr
antagonist
evalu
autoimmun
diseas
phase
clinic
trial
show
safe
welltoler
profil
healthi
subject
evalu
potent
treatment
inflammatori
bowel
diseas
dual
antagonist
test
treatment
inflammatori
autoimmun
diseas
sle
rheumatoid
arthriti
multipl
sclerosi
psoriasi
lupu
coliti
evalu
effect
gene
express
human
peripher
blood
monocyt
show
drug
could
significantli
reduc
express
inflammatori
gene
bdefensin
keratin
inhibit
tlr
ligandinduc
express
tnfa
ifna
dual
agonist
synthet
rnabas
dual
agonist
identifi
lead
drug
candid
treatment
hematolog
malign
stimul
immun
respons
mediat
express
human
dendrit
cell
bcell
monocyt
macrophag
preclin
mous
model
cancer
shown
anticanc
activ
involv
innat
adapt
immun
respons
administ
combin
approv
cancer
therapi
drug
rituximab
antibodi
bortezomib
proteasom
inhibitor
show
significantli
increas
antitumor
activ
compar
singleag
effect
sever
preclin
lymphoma
model
increas
surviv
compar
treatment
either
agent
alon
notabl
rituximab
abl
increas
activ
natur
killer
cell
indic
improv
immun
respons
enhanc
clearanc
circul
tumor
cell
compar
treatment
agent
alon
base
inhibitori
oligodeoxynucleotid
inhodn
design
c
c
g
g
c
g
g
g
g
sequenc
phosphorothioatebind
guaninemodifi
inhibitori
oligonucleotid
tlr
antagonist
compound
demonstr
promis
therapeut
effect
sle
suppress
potenti
inhibitori
activ
effici
improv
capac
reduc
immun
signal
human
immun
cell
among
deriv
ommler
et
al
design
divers
antagonist
describ
tabl
sever
oligonucleotid
antagonist
tlr
develop
immunoregulatori
sequenc
ir
short
dna
sequenc
promis
compound
ir
sequenc
also
known
develop
treatment
sle
compound
found
block
ifna
product
human
plasmacytoid
predendrit
cell
treatment
show
reduct
serum
level
nucleicacid
specif
autoantibodi
improv
diseas
symptom
lupuspron
mice
decreas
proteinurea
glomerulonephr
endorgan
damag
result
increas
surviv
could
also
revers
glucocorticoid
resist
sle
thu
could
potenti
use
corticosteroidspar
drug
administr
drug
hivstimul
peripher
blood
monocyt
cell
also
led
decreas
ifna
product
suggest
potenti
therapeut
opportun
treat
hiv
infect
ir
sequenc
specif
antagonist
evalu
pawar
et
al
lupu
mous
model
studi
autoimmun
diabet
also
conduct
anoth
tlr
dual
antagonist
enter
phase
ib
iia
studi
safeti
healthi
volunt
patient
activ
sle
although
administr
well
toler
fail
achiev
endpoint
reduc
ifnaregul
gene
unfortun
outcom
end
clinic
develop
compound
ever
sinc
herein
gather
clinic
trial
tlr
mention
studi
relat
biolog
activ
name
compound
last
updat
januari
tabl
among
three
fda
emaapprov
tlr
agonist
one
target
tlr
discuss
review
agonist
imiquimod
regard
other
bcg
agonist
tlr
possibl
monophosphoryl
lipid
mpl
agonist
tlr
inde
despit
effort
research
tabl
inhodn
sequenc
sequenc
tlr
inhibitori
activ
c
c
g
g
c
g
g
g
g
g
c
c
g
g
c
e
g
g
g
g
c
c
g
g
c
g
e
g
g
g
c
c
g
g
c
g
g
g
g
c
c
g
g
c
g
g
g
g
g
c
e
g
g
g
g
g
g
c
g
g
g
g
pharmacolog
modul
reach
final
stage
clinic
studi
either
drug
adjuv
due
obstacl
difficult
overcom
exampl
toxic
relat
immunomodul
compound
could
modul
deliv
potent
therapi
local
intratumor
intraderm
thu
directli
target
patholog
site
andor
cell
popul
moreov
anim
model
reflect
exactli
human
immunolog
pathway
allow
appreci
potenti
certain
compound
less
genet
variabl
anim
model
margin
error
possibl
predict
safeti
activ
dose
human
specif
molecular
alter
mutat
due
evolut
patholog
could
also
prevent
potent
modul
mediat
expect
therapeut
effect
addit
hostrel
characterist
gender
age
gene
polymorph
variant
despit
barrier
mention
number
clinic
trial
relat
biolog
activ
tlr
ligand
perfectli
illustr
interest
research
modul
therapeut
purpos
tolllik
receptor
demonstr
key
role
immunolog
protect
host
bodi
invad
pathogen
endogen
releas
hazard
molecul
improv
block
activ
tlr
capabl
modifi
inher
signal
pathway
thu
mediat
host
respons
render
ingeni
tool
target
therapeut
purpos
wide
spectrum
diseas
associ
tlr
directli
indirectli
aggrav
patholog
condit
mani
pharmaceut
compani
research
institut
therebi
develop
specif
tlr
modul
preclin
clinic
evalu
tlr
ligand
primarili
use
adjuv
boost
immun
system
trigger
humor
andor
cellmedi
respons
agonist
also
develop
drug
fight
viral
infect
prevent
andor
treat
cancer
antagonist
develop
downregul
tlr
overact
tool
treatment
inflammatori
autoimmun
diseas
synthet
tlr
ligand
small
molecul
belong
divers
chemic
seri
also
macromolecul
oligonucleotid
peptid
protein
ration
drug
design
small
molecul
agonist
antagonist
may
help
recent
knowledg
tlr
threedimension
structur
potenti
nontradit
approach
use
mirna
overlook
trial
involv
tlr
ligand
adjuv
numer
consid
drug
moreov
imbal
number
agonist
antagonist
clinic
investig
could
explain
recent
understand
implic
patholog
signal
dysregul
explos
number
clinic
studi
launch
wit
decreas
recent
year
even
ligand
perform
well
advanc
clinic
trial
clinic
success
gener
limit
research
still
overcom
obstacl
inde
anim
model
allow
appreci
biolog
activ
tlr
modul
reflect
exactli
happen
human
trial
due
genet
variabl
among
other
specif
molecular
alter
mutat
may
also
prevent
potent
modul
mediat
expect
therapeut
effect
research
aim
reduc
system
toxic
immunomodul
compound
modul
formul
liposom
hydrogel
nanoparticl
instig
way
administr
intratumor
intraderm
mani
studi
reveal
import
combin
therapi
includ
tlr
modul
obtain
conveni
result
immunotherapi
reveal
good
approach
complet
tradit
clinic
manag
even
similar
tlr
mechan
action
specif
remain
elucid
specif
induc
respons
singl
receptor
moreov
anim
model
reflect
potent
human
respons
drug
differ
tlr
express
activ
human
mice
continu
research
around
tlr
biolog
would
allow
find
novel
therapi
address
unmet
medic
need
cancer
diabet
rheumatoid
arthriti
system
lupu
erythematosu
alzheim
diseas
chronic
neuropath
pain
author
declar
known
compet
financi
interest
person
relationship
could
appear
influenc
work
report
paper
